2026-07-03 · testosterone, TRT, hypogonadism, body composition, men's health, TRAVERSE, endocrinology · 18 min read

Will TRT help me lose weight?

Not on the scale, and not the way a GLP-1 medication does. Corona 2016 in the Journal of Sexual Medicine pooled 59 randomized trials of testosterone replacement in men with confirmed hypogonadism and found a mean fat-mass reduction of about 1.7 kg and a mean lean-mass gain of about 1.9 kg at 12 weeks or longer. The scale often barely moves because the fat loss is offset by the muscle gain — the body-composition shift is real, but the number on the scale is not. In men who are still eating in a 500-kcal deficit and lifting weights, TRT stacks on top of that work and preferentially strips visceral fat (Traish 2014 Journal of Andrology). It is not a fix for a discipline problem, it does not replace a calorie deficit, and it is not appropriate if your total testosterone is low-normal without symptoms. See our low testosterone and weight loss guide for the diagnostic picture and our weight loss for men guide for the surrounding routine.

How much fat and muscle change should I expect on TRT?

Corona 2016's meta-analysis in the Journal of Sexual Medicine — 59 randomized trials in confirmed hypogonadal men — is the cleanest lookup: mean fat-mass loss ~1.7 kg and mean lean-mass gain ~1.9 kg at 12 weeks or longer versus placebo. Ng Tang Fui 2016 in JAMA Internal Medicine layered TRT onto a diet program in obese men with low testosterone and saw additive fat loss versus diet alone, with better preservation of lean mass on the TRT arm. Bhasin 1996 in the New England Journal of Medicine — a supraphysiologic-dose mechanism paper, not a treatment recommendation — showed that androgen receptor–mediated satellite cell activation is dose-related. The 24- and 36-month time-course data from the T-Trials (Snyder 2016 New England Journal of Medicine) and the Corona meta-analysis suggest most of the fat-mass and lean-mass shift plateaus by 12 to 24 months at typical replacement doses.

How do I know if I actually need TRT?

The Endocrine Society Clinical Practice Guideline (Bhasin 2018 Journal of Clinical Endocrinology and Metabolism) and the AUA 2023 Guideline on Testosterone Deficiency are aligned: TRT is only appropriate when you have two morning fasting total testosterone measurements below 264 ng/dL together with symptoms — reduced libido, erectile dysfunction, fatigue, mood change, loss of morning erections, reduced body hair, decreased muscle mass. A single low number is not a diagnosis; testosterone varies diurnally and pulsatilely, and non-fasting or afternoon samples are often falsely low. Reversible causes have to be ruled out first: obesity, obstructive sleep apnea, opioid use, chronic alcohol use, high-dose glucocorticoids, uncontrolled diabetes, and severe stress can all suppress the hypothalamic-pituitary-gonadal axis. Grossmann 2018 documented that 5 to 10 percent weight loss normalizes testosterone in many men with obesity-related functional hypogonadism, without ever needing TRT.

Is TRT safe for my heart after TRAVERSE?

For typical hypogonadal men with cardiovascular risk factors, yes — this is the biggest 2023 update in the field. Lincoff 2023 in the New England Journal of Medicine reported the TRAVERSE trial: 5,246 men aged 45 to 80 with confirmed hypogonadism and preexisting cardiovascular disease or high risk, randomized to transdermal testosterone gel versus placebo and followed a median of 33 months. Testosterone was non-inferior to placebo for major adverse cardiovascular events (MACE), meaning no signal of harm on the primary composite endpoint. This substantially reframed a picture that had been unsettled since Basaria 2010 (TOM trial in the New England Journal of Medicine, halted early for adverse events in frail elderly men) and Vigen 2013 (VA observational analysis in JAMA, later criticized on methodological grounds). TRAVERSE did detect small absolute-risk increases in atrial fibrillation, acute kidney injury, and pulmonary embolism — worth discussing, but the primary MACE story is reassuring.

Does TRT affect fertility?

Yes, and this is the single most common blindside for men in their 30s and 40s. Ramasamy 2015 in BJU International is the standard reference: exogenous testosterone suppresses pituitary luteinizing hormone and follicle-stimulating hormone, which suppresses testicular testosterone production and spermatogenesis — sperm counts fall, testicular volume shrinks, and infertility is the rule rather than the exception on monotherapy TRT. If paternity is a goal in the next 1 to 3 years, TRT monotherapy is not the right choice. Fertility-preserving alternatives include clomiphene 25 mg every other day (a selective estrogen receptor modulator that stimulates endogenous testosterone production) or hCG 500 to 1,000 IU two to three times a week alongside TRT to maintain intratesticular testosterone and spermatogenesis. Even with hCG cover, some men experience persistent oligospermia; men who complete family planning first and start TRT afterwards avoid this trade-off entirely. Sperm cryopreservation before starting TRT is a reasonable option for men with unclear future plans.

What about a wellness-clinic TRT prescription?

Be careful. Legitimate TRT is prescriber-mediated, starts from two confirmed morning fasting total testosterone measurements below 264 ng/dL with symptoms (Bhasin 2018), involves ruling out reversible causes (Grossmann 2018), and includes lifelong hematocrit and PSA monitoring (Ohlander 2018 Sexual Medicine Reviews for hematocrit; AUA 2023 for PSA). A wellness clinic or pellet mill that prescribes testosterone off a single afternoon number, off a symptom questionnaire alone, or at supraphysiologic doses targeting total testosterone above 900 to 1,200 ng/dL is not practicing TRT — that is anabolic steroid use with different risks: erythrocytosis, prostate effects, gynecomastia, mood destabilization, cardiovascular strain, and, in men who later stop, prolonged hypogonadism from suppressed pituitary function. If a clinic will not do baseline LH, FSH, prolactin, iron studies, hematocrit, PSA (age 40+), and lipid panel, and will not schedule follow-up hematocrit at 3 to 6 months, walk away and see an endocrinologist or urologist instead.

Can I take TRT with a GLP-1 medication?

Yes, and for many men the combination is additive. GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound) drive most of the fat-mass loss; TRT preserves lean mass and preferentially strips visceral fat on top of that. There is no direct pharmacologic interaction between exogenous testosterone and GLP-1 receptor agonists. The behavioral overlay matters: TRT improves energy and libido at 3 to 6 months (Snyder 2016 T-Trials in the New England Journal of Medicine), and men who feel better on TRT reliably increase daily activity, which is downstream of feeling better rather than a direct drug effect. Coordinate the prescriber — usually your endocrinologist or urologist for TRT and your primary-care or obesity-medicine clinician for the GLP-1 — because TRT can raise hematocrit and the GLP-1 can drop appetite in ways that both need monitoring in the same visit. See our GLP-1 weight loss overview and prescription weight loss medications guides.

Will I need TRT forever?

For most men with true primary or organic secondary hypogonadism — Klinefelter syndrome, prior cranial radiation, pituitary tumor, testicular injury, congenital hypogonadotropic hypogonadism — yes, TRT is lifelong. For men with obesity-related or opioid-induced functional hypogonadism, the answer is often no. Grossmann 2018 documented that 5 to 10 percent weight loss reverses functional hypogonadism in a substantial fraction of men, and treating the underlying opioid dependence, obstructive sleep apnea, or heavy alcohol use can restore endogenous testosterone production. The T4DM trial (Wittert 2021 in The Lancet Diabetes and Endocrinology) showed that TRT plus lifestyle prevented type 2 diabetes better than lifestyle alone in men with waist circumference at least 95 cm and low-normal testosterone, but T4DM was a prevention trial rather than a lifelong-treatment endorsement. Discuss a trial-off with your prescriber at 12 to 18 months if the underlying driver is functional and has been addressed.

What if my testosterone is low-normal without symptoms?

No TRT. Bhasin 2018 and AUA 2023 are explicit: TRT is not appropriate for low-normal total testosterone in the absence of symptoms, and it is not appropriate as an anti-aging or general-wellness intervention. A single number of 300 to 450 ng/dL in a man who has normal libido, morning erections, energy, and body composition is a normal number, not a diagnosis. The T-Trials (Snyder 2016 New England Journal of Medicine) selected men aged 65 and older with unequivocal hypogonadism (total testosterone below 275 ng/dL) plus symptoms and still found modest sexual and physical-function benefits with mixed effects on cognition and vitality — meaning even in confirmed cases the effect size on quality-of-life endpoints is smaller than most wellness marketing suggests. If you are considering TRT primarily for weight loss, energy, or gym performance without confirmed hypogonadism, the honest recommendation is to address sleep, resistance training, protein intake, and body-fat percentage first — see our low testosterone and weight loss and weight loss for men guides.

TRT and Weight: Fat Mass, Lean Mass, and What TRAVERSE Changed

Quick stats

• Diagnostic threshold for testosterone deficiency (Bhasin 2018 Endocrine Society): two morning fasting total testosterone measurements below 264 ng/dL with symptoms
• Body-composition effect on TRT (Corona 2016 J Sex Med, 59 RCTs): mean fat-mass loss ~1.7 kg and mean lean-mass gain ~1.9 kg at ≥12 weeks
• Type 2 diabetes prevention on TRT + lifestyle (Wittert 2021 T4DM, Lancet Diabetes Endocrinol): ~41% relative reduction in incident T2D versus lifestyle alone in men aged 50–74 with waist ≥95 cm and low-normal T
• Cardiovascular safety (Lincoff 2023 TRAVERSE, NEJM): testosterone non-inferior to placebo for MACE at 33 months in 5,246 men with hypogonadism and CV risk
• Hematocrit monitoring cadence (Ohlander 2018 Sex Med Rev): check at baseline, 3–6 months, then annually; hold and reassess if Hct > 54%
• 911 red flags on TRT: new chest pain, focal neurologic deficit, or sudden shortness of breath with calf swelling — emergency evaluation for MI, stroke, or pulmonary embolism

The honest picture, in one paragraph

Testosterone replacement therapy is not a weight-loss drug — the mean fat-mass loss is roughly 1.7 kg and the mean lean-mass gain is roughly 1.9 kg at 12 weeks or longer in confirmed hypogonadism (Corona 2016, Journal of Sexual Medicine, pooling 59 RCTs), which means the number on the scale often barely moves. What TRT is, is a body-composition-shift drug that preferentially strips visceral fat, preserves and builds lean mass, and improves insulin sensitivity, bone density, sexual function, and mood in men with confirmed hypogonadism — defined by Bhasin 2018 (Journal of Clinical Endocrinology and Metabolism) and the AUA 2023 Guideline on Testosterone Deficiency as two morning fasting total testosterone measurements below 264 ng/dL together with symptoms. The 2023 TRAVERSE trial (Lincoff 2023, NEJM, 5,246 men followed a median of 33 months) removed the older MACE concern in typical hypogonadal men with cardiovascular risk factors. TRT will not fix a discipline problem, does not replace a 500-kcal deficit, is not appropriate for low-normal total testosterone without symptoms, and must be prescriber-mediated with monitoring — do not source it from a wellness clinic that skips confirmatory testing, ignores reversible causes, or targets supraphysiologic totals; that is anabolic steroid use with different risks, not TRT.

How TRT is delivered

TRT is prescribed in several formulations. The receptor pharmacology is the same across preparations — the differences are kinetics, cost, injection burden, and side-effect profile.

Why TRT shifts body composition

Four mechanistic threads explain the fat-mass loss and lean-mass gain seen in Corona 2016. None of them describe a direct calorie-burning effect — they describe why the same eating pattern produces a different body composition when circulating testosterone is repleted.

1. Androgen receptor–mediated satellite cell activation

Bhasin 1996 (New England Journal of Medicine) — a supraphysiologic mechanism paper, not a treatment recommendation — showed that testosterone activates skeletal muscle satellite cells and drives fiber hypertrophy in a dose-related pattern, with the largest effects when combined with resistance training. At typical replacement doses in hypogonadal men, the lean-mass gain is smaller than in the supraphysiologic study (roughly 1.9 kg in Corona 2016) but is real and reproducible. This is the biology behind the muscle-mass and strength endpoints in the Snyder 2016 T-Trials (NEJM) physical-function arm.

2. Adipose lipolysis and preferential visceral-fat loss

Traish 2014 (Journal of Andrology) reviewed the adipose-tissue evidence: androgen receptor stimulation increases lipolysis, downregulates lipoprotein lipase in visceral adipose tissue, and shifts fat distribution from visceral to subcutaneous depots — the visceral-fat compartment is more responsive than subcutaneous fat, which is why waist circumference often decreases more than body-mass index on TRT. This is the mechanism behind the disproportionate cardiometabolic benefit seen in Wittert 2021 (T4DM) despite modest total fat-mass change.

3. Insulin sensitivity and glucose disposal

Wittert 2021 (Lancet Diabetes and Endocrinology) — the T4DM trial — randomized 1,007 men aged 50 to 74 with waist circumference at least 95 cm and low-normal testosterone (baseline total T ≤ 14 nmol/L) to lifestyle plus testosterone undecanoate versus lifestyle plus placebo and reported a 41% relative reduction in incident type 2 diabetes in the testosterone arm at 2 years. Jones 2011 (Diabetes Care) — the TIMES-2 study — showed insulin-sensitivity improvement in hypogonadal men with type 2 diabetes or metabolic syndrome. The signal is downstream of muscle-mass gain, visceral-fat loss, and direct effects on insulin receptor cascade. See insulin resistance and weight loss and metabolic syndrome and weight loss.

4. Behavioural — energy, libido, and downstream activity

Snyder 2016 (NEJM) T-Trials followed 790 men aged 65 and older with confirmed hypogonadism and reported modest but statistically significant improvements in sexual function, walking distance, and mood at 12 months on TRT gel. Snyder 2018 (JAMA Internal Medicine) extended the sexual-function endpoint. The mechanism is not direct calorie burn — it is that men who feel better sleep better, walk more, and re-engage with structured exercise. The behavioural overlay accounts for a substantial fraction of the real-world body-composition effect and is the reason TRT stacks so well with a coached routine.

Dose-response and time-course

The trajectory is not linear. Testosterone rises fastest, hematocrit and PSA lag, fat mass and lean mass shift steadily through the first year, and A1c improvement tracks the visceral-fat change.

5-step TRT-and-weight protocol

This is the pathway that matches the Bhasin 2018 Endocrine Society guideline and the AUA 2023 Guideline on Testosterone Deficiency. Every step is prescriber-mediated.

Step 1: Confirm the diagnosis — two morning fasting total testosterone measurements plus symptoms

Bhasin 2018 and AUA 2023 are aligned. The diagnostic threshold is two morning (before 10 a.m.) fasting total testosterone measurements below 264 ng/dL, drawn on separate days at least a week apart, together with symptoms of testosterone deficiency: reduced libido, erectile dysfunction, loss of morning erections, fatigue, mood change, reduced body hair, decreased muscle mass, and increased body fat. A single low afternoon value is not a diagnosis. Free testosterone helps only when sex hormone–binding globulin is abnormal (obesity, chronic illness, hyperthyroidism, hepatitis) — the calculated or measured free testosterone threshold is roughly 70 pg/mL (Bhasin 2018).

Step 2: Address reversible causes before prescribing TRT

Grossmann 2018 documented that 5 to 10% weight loss normalizes testosterone in a substantial fraction of men with obesity-related functional hypogonadism — the aromatase pathway in adipose tissue converts testosterone to estradiol, and losing visceral fat reverses that suppression (Diaz-Arjonilla 2009, International Journal of Impotence Research). Obstructive sleep apnea with CPAP therapy and weight loss is the frequent right first move. Opioid-induced hypogonadism responds to opioid taper and non-opioid pain strategies — see opioids and weight changes. Chronic heavy alcohol use, high-dose glucocorticoids, and uncontrolled diabetes all suppress the hypothalamic-pituitary-gonadal axis and are addressable. In many men in their 30s and 40s, the reversible-cause pathway is the correct first step.

Step 3: Baseline labs before starting TRT

At minimum: total testosterone (×2 morning fasting), free testosterone if SHBG is suspect, LH and FSH (to distinguish primary from secondary hypogonadism), prolactin (pituitary screen), iron studies (hemochromatosis), hematocrit (baseline for monitoring), PSA if age ≥40 or family history, lipid panel, and a comprehensive metabolic panel. Hemoglobin A1c is reasonable if metabolic risk is present. If LH and FSH are elevated with low testosterone, the picture is primary (testicular) hypogonadism. If LH and FSH are inappropriately normal or low with low testosterone, the picture is secondary (pituitary or hypothalamic) — and prolactin plus a morning cortisol are worth adding.

Step 4: Choose formulation with the patient

Transdermal gel for steady kinetics and easier titration; IM cypionate for cost; long-ester undecanoate or pellets for adherence; nasal or SubQ for men who want to preserve fertility longer. If paternity is a near-term goal (next 1 to 3 years), consider clomiphene 25 mg every other day or adding hCG 500 to 1,000 IU two to three times weekly to preserve spermatogenesis (Ramasamy 2015, BJU International). See erectile dysfunction and weight loss for the sexual-function overlay.

Step 5: Monitor lifelong — total T, hematocrit, PSA, fertility, and symptoms

Ohlander 2018 (Sexual Medicine Reviews): hematocrit at baseline, 3 to 6 months, then annually; hold and re-evaluate if Hct >54%. Total testosterone at 3 to 6 months (mid-cycle for IM); target the middle third of the normal range (roughly 500 to 800 ng/dL). PSA at 6 to 12 months if age ≥40 — urology referral for any rise >1.4 ng/mL in a year or a new prostate nodule (AUA 2023). Fertility counselling at every visit if paternity is on the table. Bone density every 2 years in men who started TRT for confirmed hypogonadism with baseline low BMD (Katznelson 1996, JCEM).

What treatments actually do — comparison

Special situations

Obesity-related functional hypogonadism

Diaz-Arjonilla 2009 (International Journal of Impotence Research) documented the bidirectional pathway: adipose-tissue aromatase converts testosterone to estradiol, estradiol suppresses the hypothalamic-pituitary-gonadal axis, and the resulting low testosterone favors further fat gain and muscle loss. The loop is tractable. Grossmann 2018 showed that 5 to 10 percent weight loss normalizes testosterone in a substantial fraction of men, and the T4DM trial (Wittert 2021) confirmed that even in men with low-normal T, lifestyle plus TRT beats lifestyle alone for diabetes prevention — but T4DM was a prevention trial, not a lifelong-TRT endorsement. The pragmatic sequence is: 6 to 12 months of structured weight loss (calorie deficit, resistance training, preserve muscle during weight loss, strength training for weight loss), a repeat morning fasting total testosterone at goal weight, and TRT only if the number stays below 264 ng/dL with persistent symptoms.

Type 2 diabetes and metabolic syndrome

The T4DM trial (Wittert 2021, Lancet Diabetes and Endocrinology) is the strongest efficacy signal in this population: in men aged 50 to 74 with waist ≥95 cm and low-normal T, testosterone undecanoate on top of a lifestyle program produced a 41% relative reduction in incident type 2 diabetes at 2 years. Jones 2011 (TIMES-2, Diabetes Care) showed insulin-sensitivity improvement in hypogonadal men with T2D or metabolic syndrome. Grossmann 2020 (Lancet Diabetes and Endocrinology) framed the field. The men who benefit most are the ones with true hypogonadal symptoms, confirmed low or low-normal T, and cardiometabolic risk; the effect size on scale weight is small, but the visceral-fat, A1c, and blood-pressure effects layer meaningfully. See insulin resistance and weight loss and metabolic syndrome and weight loss.

Opioid-induced hypogonadism

Chronic opioid use suppresses the hypothalamic-pituitary-gonadal axis at every level, and men on long-term opioid therapy for pain or on MOUD (methadone, buprenorphine) frequently develop low testosterone, low libido, fatigue, and body-composition change. The right first move is often opioid taper or transition to a lower-dose alternative rather than TRT — see opioids and weight changes for the full framing. When opioid taper is not appropriate (chronic cancer pain, palliative context, MOUD in stable recovery) and confirmed low testosterone with symptoms persists, TRT is a reasonable add-on with the standard monitoring cadence.

Fertility preservation on TRT

Ramasamy 2015 (BJU International) is the reference. Exogenous testosterone suppresses pituitary LH and FSH, which suppresses intratesticular testosterone and spermatogenesis; sperm counts typically fall by 12 weeks and testicular volume shrinks. Men who want to preserve fertility while on TRT can add hCG 500 to 1,000 IU subcutaneously two to three times a week to maintain intratesticular testosterone. Clomiphene 25 mg every other day is a fertility-preserving alternative to TRT monotherapy — clomiphene stimulates endogenous LH and FSH release, so testicular testosterone production and spermatogenesis are preserved. Both options are prescriber-mediated. Sperm cryopreservation before starting TRT is a reasonable option for men with unclear future plans; testicular sperm extraction is available for men who have already been on TRT for years and want to reverse suppression.

Cardiovascular safety after TRAVERSE (2023)

Lincoff 2023 (NEJM), the TRAVERSE trial, is the biggest 2023 update. TRAVERSE randomized 5,246 men aged 45 to 80 with confirmed hypogonadism and preexisting cardiovascular disease or high CV risk to transdermal testosterone gel versus placebo and followed them a median of 33 months. Testosterone was non-inferior to placebo for major adverse cardiovascular events (composite of CV death, non-fatal MI, non-fatal stroke). TRAVERSE substantially reframed the field. Basaria 2010 (TOM, NEJM) had been halted early for adverse CV events, but the TOM cohort was frail elderly men, not typical hypogonadal men with CV risk; Vigen 2013 (JAMA) was a VA observational analysis with methodological concerns and has been superseded by TRAVERSE. That said, TRAVERSE did detect small absolute-risk increases in atrial fibrillation, acute kidney injury, and pulmonary embolism (Ide 2020 VTE signal). Defer TRT when the picture is a recent MI, an active PSA workup, untreated OSA, or uncontrolled polycythemia.

TRT plus GLP-1 medication

For men with confirmed hypogonadism who also qualify for GLP-1 therapy, the combination is often additive: the GLP-1 drives most of the fat-mass loss; TRT preserves and builds lean mass and preferentially strips visceral fat; the behavioural overlay (energy, libido, activity) compounds. There is no direct pharmacologic interaction. Coordinate the prescriber — usually endocrinology or urology for TRT and primary care or obesity medicine for the GLP-1 — because hematocrit monitoring on TRT and GI side-effect management on the GLP-1 both need attention in the same visit. See GLP-1 weight loss overview, GLP-1 medications compared, and prescription weight loss medications.

Red flags — when to see a doctor

Some findings on TRT are not routine and warrant same-day or same-week evaluation. If any of these are severe or acute, call 911 or go to the nearest emergency department.

• New chest pain, stroke symptoms (facial droop, arm weakness, speech change), or sudden shortness of breath with calf swelling — emergency evaluation for MI, stroke, or pulmonary embolism (Lincoff 2023 TRAVERSE detected small absolute-risk increases in AF, AKI, and PE; Ide 2020 VTE signal).
• Hematocrit >54% — hold TRT, phlebotomize per Ohlander 2018 (Sexual Medicine Reviews), reassess formulation and dose; erythrocytosis raises stroke and VTE risk.
• Rising PSA (>1.4 ng/mL change in a year) or a new prostate nodule on exam — urology referral per AUA 2023; TRT does not cause prostate cancer, but it can accelerate an existing occult one.
• New unilateral calf swelling and pain, or unilateral leg heaviness — DVT workup with Doppler ultrasound (Ide 2020).
• New gynecomastia, breast tenderness, or significant fluid retention — reassess dose and aromatase activity; may warrant SHBG-adjusted free T and estradiol.
• Mood destabilization, irritability, or aggression at supraphysiologic dosing — this is a wellness-clinic pattern, not TRT. Wellness-clinic supraphysiologic dosing targeting total testosterone above 900 to 1,200 ng/dL without confirmatory diagnostic labs is not TRT — it is anabolic steroid use with different risks, and the fix is to see an endocrinologist or urologist.

How this connects to the rest of the site

TRT sits in the men’s-endocrine cluster and overlaps with several other guides. For the diagnostic and reversible-cause picture, see low testosterone and weight loss and erectile dysfunction and weight loss. For the everyday routine around a TRT protocol, see weight loss for men, preserve muscle during weight loss, and strength training for weight loss. For the reversible-cause pathway, see sleep apnea and weight loss and opioids and weight changes. For the metabolic-syndrome and insulin-resistance overlay, see metabolic syndrome and weight loss and insulin resistance and weight loss. For tracking the body-composition shift, see body fat percentage and body recomposition. For medication options on top, see prescription weight loss medications and weight loss drug safety.

TRT and weight FAQ

Will TRT help me lose weight? Not on the scale — expect ~1.7 kg fat loss offset by ~1.9 kg lean-mass gain (Corona 2016).

How do I know I actually need it? Two morning fasting total T <264 ng/dL with symptoms, reversible causes ruled out (Bhasin 2018; AUA 2023; Grossmann 2018).

Is it safe for my heart after TRAVERSE? For typical hypogonadal men with CV risk, yes — non-inferior to placebo for MACE at 33 months (Lincoff 2023).

Does it affect fertility? Yes — monotherapy TRT suppresses spermatogenesis; pair with hCG or use clomiphene if fertility is a goal (Ramasamy 2015).

Wellness-clinic prescription? Walk away if they skip confirmatory labs, ignore reversible causes, or target supraphysiologic totals — that is anabolic steroid use, not TRT.

Can I take it with a GLP-1? Yes — no direct interaction; coordinate the prescribers.

Will I need it forever? Primary hypogonadism, yes; functional hypogonadism, often no once the driver is addressed (Grossmann 2018).